Enabling novel fusion detection for lung cancer management

SOPHiA DDM™ Dx RNAtarget Oncology Solutions (ROS), now CE-IVD and delivers a streamlined workflow from sample to report for a reduced time-to-patient benefit.

Get actionable insight into your lung cancer patient’s management with our RNAtarget Technology detecting not only known but also novel fusions in newly emerging biomarkers.

Contact us to know more